Results 171 to 180 of about 2,753,395 (319)

Understanding cancer cell plasticity: EMT, respecialisation, and therapeutic opportunities. [PDF]

EMBO Mol Med
Morel AP, Ouzounova M.
europepmc   +1 more source

Cancer Cell Dissemination During Surgical Manipulation

, 1963
Tetsuo Maki, Susumu Majima, Koichi Yoshida, Toshio Takahashi   +3 more
openalex   +2 more sources

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira, Anna Skwarska, Karolina Chwialkowska, Agnieszka Ostrowska, Gabriela Sokolowska, Anna Zeller, Anna Erol, Andrzej Eljaszewicz, Bartosz Hanczaruk, Anna Michalska‐Falkowska, Agnieszka Tarasik, Joanna Reszec‐Gielazyn, Pawel Knapp, Marcin Moniuszko, Adam Kretowski   +14 more
wiley   +1 more source

Lysosomes in cancer cells [PDF]

Journal of Clinical Pathology, 1974
openaire   +4 more sources

Decoding the cancer cell proteome: A delicate equilibrium with the genome and epigenome. [PDF]

Neuro Oncol
Duchatel RJ, Nazarian J.
europepmc   +1 more source

Tissue T and B cell infiltration of primary and metastatic cancer. [PDF]

, 1976
Gunnar Husby, Peter Hoagland, R. G. Strickland, Ralph C. Williams   +3 more
openalex   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

The interplay of DNA damage, epigenetics and tumour heterogeneity in driving cancer cell fitness. [PDF]

Nat Commun
Rouault CD, Charafe-Jauffret E, Ginestier C.   +2 more
europepmc   +1 more source

New Histochemical Methods for Lipids and the Lipids in Cancer Cells

, 1960
Yukio Ishiwatari, Genichi OSHIDA, Hideo Matsuzaki   +2 more
openalex   +2 more sources

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source